Cancer in Men and Treatment Characteristics

Key Findings & Data:Methods: We reviewed retrospectively the medical records of 16 male breast cancer patients who were treated in our clinic between June 2004 and January 2013.

💡

Conclusion & Impact:Early diagnosis and treatment can result in good prognosis for male patients with breast cancer.

🔬Design:Review & Systematic Survey

📍Scope:2004 Verileri

⚙️Variables:Domain Parameters

Abstract

Background: The aim of this study was to evaluate cases of male breast cancer treated at our clinic. Methods: We reviewed retrospectively the medical records of 16 male breast cancer patients who were treated in our clinic between June 2004 and January 2013. Patient age, tumor localization, tumor stage, histopathologic characteristics, genetic properties, adjuvant therapy, and survival were analyzed. Results: Patients ranged in age from 44 to 82 and the average age was 62. Tumors were localized in the left breast in 11 patients and in the right breast in 4 patients. Using the AJCC 2010 staging, 6 patients were stage 2, 4 patients were stage 3A, 3 patients were stage 3B, and 2 patients were stage 3C. All of the cases involved invasive ductal carcinoma. In all patients, modified radical mastectomy followed by adjuvant chemotherapy and radiotherapy was administered. The median disease free survival was 46 months (12-108). Conclusion: Male breast cancer is associated with clinical, histopathological and prognostic features that are similar to female breast cancer and should be treated based on the same principles. Early diagnosis and treatment can result in good prognosis for male patients with breast cancer.

Özet

Amaç: Bu çalışmamızda amacımız kliniğimizde tedavi edilen erkek meme kanseri (EMK) olgularını literatür bilgisi ışı- ğında sunmaktır. Gereç ve Yöntem: Bu geriye dönük çalışmada Haziran 2004 ile Ocak 2013 tarihleri arasında kliniğimizde incelenen ve tedavi edilen 15 erkek hastanın kayıtları incelendi. Hasta yaşı, tümörün hangi memeden geliştiği, tümör evresi, histopatolojik özellikler, genetik özellikler, adjuvan tedaviler ve sağkalım süreleri analiz edildi. Bulgular: Hastalar 44-82 yaşları arasında, ortalama 62 yaşındaydı. Tümör 11 hastada sol memede, dört hastada sağ memede yerleşimli idi. AJCC 2010 evrelemesine göre altı hasta evre 2, dört hasta evre 3A, üç hasta evre 3B ve iki hasta evre 3C idi. Hastalarımızın tamamı invaziv duktal karsinomdu. Hastalarımızın hepsine modifiye radikal mastektomi sonrası adjuvan kemoterapi ve radyoterapi uygulanmıştı. Hastalıksız sağkalım medyan 46 (12-108) ay bulundu. Sonuç: Erkek meme kanserleri kadın meme kanserlerine benzer klinik, histopatolojik ve prognostik özellikler göstermekte olup, aynı prensiplerle tedavi edilmelidir. Erkek meme kanserine erken evrede tanı konulur ve uygun tedavi yapılırsa prognoz iyi görünmektedir.

🔖

Cite This Article

EKİCİ, K., TEMELLİ, Ö., EKİCİ, C. (2022). Cancer in Men and Treatment Characteristics. Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 26 - Sayı: 1, 42–46. https://ajindex.com/articles/571329

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (17)

Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist 2005;10(7):471-9
Uğurluer G, İlhan M, Edirne T, Şahin HA, Turan N. Erkek Meme Kanserleri. Van Tıp Dergisi 2009;16(1):1-5
Eroğlu A, Ersöz Ş. Erkek Meme Kanseri. Yeni Tıp Dergisi 2010;27:202-7
Hill TD, Khamis HJ, Tyczynski JE, Berkel HJ. Comparison of male and female breast cancer incidence trends, tumor characteristics, and survival. Ann Epidemiol 2005;15(10):773-80
Park S, Kim JH, Koo J, Park BW, Lee KS. Clinicopathological characteristics of male breast cancer. Yonsei Med J 2008;49(6):978-86
Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 2004;83(1):77-86
Crew KD, Neugut AI, Wang X, Jacobson JS, Grann VR, Raptis G, et al. Racial disparities in treatment and survival of male breast cancer. J Clin Oncol 2007;25(9):1089-98
Sevinç Aİ, Canda AE, Atila K, Canda T, Harmancıoğlu Ö, Saydam S, ve ark. Erkeklerde meme kanseri: 22 olgu. Meme Sağlığı Dergisi 2007;3(1):14-8
El Omari-Alaoui H, Lahdiri I, Nejjar I, Hadadi K, Ahyoud F, Hachi H, et al. Male breast cancer. A report of 71 cases. Cancer Radiother 2002;6(6):349-51
Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonasson JG, Tryggvadottir L, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 1997;60(5):1079-84
Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med 2010;12(5):245-59
Vetto J, Jun SY, Paduch D, Eppich H, Shih R. Stages at presentation, prognostic factors, and outcome of breast cancer in males. Am J Surg 1999;177(5):379-83
Goss PE, Reid C, Pintilie M, Lim R, Miller N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955- 1996. Cancer 1999;85(3):629-39
Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, et al. CHEK2 1100delC and male breast cancer in the Netherlands. Breast Cancer Res Treat 2009;116(2):397-400
Koc M, Polat P. Epidemiology and aetiological factors of male breast cancer: a ten years retrospective study in eastern Turkey. Eur J Cancer Prev 2001;10(6):531-4
Wittliff JL. Specific receptors of the steroid hormones in breast cancer. Semin Oncol 1974;1(2):109-18
Goyal A, Horgan K, Kissin M, Yiangou C, Sib